Coutens B, Yrondi A, Rampon C, Guiard B
Psychopharmacology (Berl). 2022; 239(9):2735-2752.
PMID: 35947166
DOI: 10.1007/s00213-022-06203-8.
Schatzberg A, Charles D
Psychopharmacol Bull. 2018; 48(1):64-153.
PMID: 29382960
PMC: 5765435.
Oluboka O, Katzman M, Habert J, McIntosh D, Macqueen G, Milev R
Int J Neuropsychopharmacol. 2017; 21(2):128-144.
PMID: 29024974
PMC: 5793729.
DOI: 10.1093/ijnp/pyx081.
Khoo A, Zhou H, Teng M, Lin L, Zhao Y, Soh L
CNS Drugs. 2015; 29(8):695-712.
PMID: 26293743
DOI: 10.1007/s40263-015-0267-6.
Luscher B, Fuchs T
Adv Pharmacol. 2015; 73:97-144.
PMID: 25637439
PMC: 4784429.
DOI: 10.1016/bs.apha.2014.11.003.
Comparative efficacy and risk of harms of immediate- versus extended-release second-generation antidepressants: a systematic review with network meta-analysis.
Nussbaumer B, Morgan L, Reichenpfader U, Greenblatt A, Hansen R, Van Noord M
CNS Drugs. 2014; 28(8):699-712.
PMID: 24794101
DOI: 10.1007/s40263-014-0169-z.
Fluoxetine versus other types of pharmacotherapy for depression.
Magni L, Purgato M, Gastaldon C, Papola D, Furukawa T, Cipriani A
Cochrane Database Syst Rev. 2013; (7):CD004185.
PMID: 24353997
PMC: 11513554.
DOI: 10.1002/14651858.CD004185.pub3.
Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
Bobo W, Chen H, Trivedi M, Stewart J, Nierenberg A, Fava M
J Affect Disord. 2011; 133(3):467-76.
PMID: 21601287
PMC: 10177662.
DOI: 10.1016/j.jad.2011.04.032.
The GABAergic deficit hypothesis of major depressive disorder.
Luscher B, Shen Q, Sahir N
Mol Psychiatry. 2010; 16(4):383-406.
PMID: 21079608
PMC: 3412149.
DOI: 10.1038/mp.2010.120.
gamma-Aminobutyric acid-type A receptor deficits cause hypothalamic-pituitary-adrenal axis hyperactivity and antidepressant drug sensitivity reminiscent of melancholic forms of depression.
Shen Q, Lal R, Luellen B, Earnheart J, Andrews A, Luscher B
Biol Psychiatry. 2010; 68(6):512-20.
PMID: 20579975
PMC: 2930197.
DOI: 10.1016/j.biopsych.2010.04.024.
Transforming the psychiatric inpatient unit from short-term pseudo-asylum care to state-of-the-art treatment setting.
Feifel D
Psychiatry (Edgmont). 2009; 5(9):47-50.
PMID: 19727261
PMC: 2687088.
Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity.
Schmitt A, Bauer M, Volz H, Moeller H, Jiang Q, Ninan P
Eur Arch Psychiatry Clin Neurosci. 2009; 259(6):329-39.
PMID: 19255709
DOI: 10.1007/s00406-009-0003-7.
[Antidepressive pharmacotherapy. In slight and severe disease, young and old].
Baghai T, Volz H, Moller H
Internist (Berl). 2009; 50(2):235-43.
PMID: 19183920
DOI: 10.1007/s00108-009-2320-3.
The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.
Bauer M, Tharmanathan P, Volz H, Moeller H, Freemantle N
Eur Arch Psychiatry Clin Neurosci. 2009; 259(3):172-85.
PMID: 19165525
DOI: 10.1007/s00406-008-0849-0.
Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis.
Gartlehner G, Thieda P, Hansen R, Gaynes B, DeVeaugh-Geiss A, Krebs E
Drug Saf. 2008; 31(10):851-65.
PMID: 18759509
DOI: 10.2165/00002018-200831100-00004.
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Brent D, Emslie G, Clarke G, Wagner K, Asarnow J, Keller M
JAMA. 2008; 299(8):901-913.
PMID: 18314433
PMC: 2277341.
DOI: 10.1001/jama.299.8.901.
In vivo electrophysiological assessment of the putative antidepressant Wf-516 in the rat raphe dorsalis, locus coeruleus and hippocampus.
El Mansari M, Blier P
Naunyn Schmiedebergs Arch Pharmacol. 2007; 376(5):351-61.
PMID: 18060386
DOI: 10.1007/s00210-007-0210-6.
Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis.
Weinmann S, Becker T, Koesters M
Psychopharmacology (Berl). 2007; 196(4):511-20.
PMID: 17955213
DOI: 10.1007/s00213-007-0975-9.
Innovative approaches for the development of antidepressant drugs: current and future strategies.
Schechter L, Ring R, Beyer C, Hughes Z, Khawaja X, Malberg J
NeuroRx. 2006; 2(4):590-611.
PMID: 16489368
PMC: 1201318.
DOI: 10.1602/neurorx.2.4.590.
Fluoxetine versus other types of pharmacotherapy for depression.
Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M
Cochrane Database Syst Rev. 2005; (4):CD004185.
PMID: 16235353
PMC: 4163961.
DOI: 10.1002/14651858.CD004185.pub2.
